1-3 of 3
Barry W. Miller, MS, CNP
Close
Sort by
Journal Articles

Analysis of Immune-Related Adverse Reactions in Patients with Classical Hodgkin Lymphoma (cHL) on Programmed Death-1 (PD-1) Inhibitor Therapy

Michael Brave, Jinzhong Liu, PhD, Donna Przepiorka, MDPhD, Gideon Blumenthal, MD, Barry W. Miller, MS, CNP
Journal: Blood
Blood (2018) 132 (Supplement 1): 1652.
https://doi.org/10.1182/blood-2018-99-114101
Published: 2018
Journal Articles

Hydroxyurea Utilization Patterns Among Sickle Cell Disease Patients in the United States, US FDA Sentinel Database

Rosanna Setse, MD MPH, PhD, Corinne Woods, RPh, MPH, Bindu Kanapuru, MD, Talia Menzin, BS, Justin Bohn, Sc.M., Sc.D, Justin Mathew, PharmD, David Coyle, MD, Barry W. Miller, MS, CNP, Ann T. Farrell, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2372.
https://doi.org/10.1182/blood-2018-99-116281
Published: 2018
Journal Articles

Idelalisib for Treatment of Follicular Lymphoma and Chronic Lymphocytic Leukemia in Clinical Trials Versus the Real World: Treatment Duration and Survival Are Associated with Pretreatment Modified Charlson Score

Steven T Bird, PhD PharmD, Natasha Flowers, BA, Fang Tian, PhD MHS, MPH, Donna Przepiorka, MD PhD, Tae Hyun Jung, PhD, Rongrong Wang, MPH, Zebulin Kessler, BS, Corinne Woods, RPh, MPH, Bo Kim, BA, Barry W. Miller, MS, CNP, Michael Wernecke, BA, Stephen McKean, PhD, Clara Kim, PhD, Kate Gelperin, MD MPH, Jeffrey A Kelman, MD MMSc, David J Graham, MD MPH
Journal: Blood
Blood (2018) 132 (Supplement 1): 2889.
https://doi.org/10.1182/blood-2018-99-116498
Published: 2018